Current state of ex-vivo lung perfusionSanchez, Pablo G.; Mackowick, Kristen M.; Kon, Zachary N.Current Opinion in Organ Transplantation: June 2016 - Volume 21 - Issue 3 - p 258–266 doi: 10.1097/MOT.0000000000000310 REVIEW Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The purpose of the current report is to review the ex-vivo peer-reviewed literature published in the last 5 years and to summarize the findings. Recent findings Encouraging data have been published by several centers utilizing ex-vivo lung perfusion (EVLP) as a means to identify viable grafts from the high-risk donor pool. The outcomes of transplanted lungs that were initially declined because of poor quality, but reevaluated with ex-vivo perfusion, are equivalent to standard criteria donor lungs. Further, research reports have emphasized the role of ex-vivo perfusion as a platform to improve graft quality and reduce the injurious effects of ischemia-reperfusion. Summary Over the last 10 years, EVLP has proved its value as a reassessment tool to increase donor utilization. As short- and long-term data demonstrate the safety of EVLP, its use as a therapeutic platform is emerging, along with the promise of a new era in lung transplantation. Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA Correspondence to Pablo G. Sanchez, MD, PhD, Division of Cardiac Surgery, University of Maryland School of Medicine, 110 S. Paca Street, 7th Floor, Baltimore, MD 21201, USA. Tel: +1 410 328 5842; fax: +1 410 328 2750; e-mail: email@example.com Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.